Loading...
XSHG
600594
Market cap430mUSD
Sep 30, Last price  
3.64CNY
Name

Guizhou Yibai Pharmaceutical Co Ltd

Chart & performance

D1W1MN
XSHG:600594 chart
P/E
—
P/S
1.56
EPS
—
Div yield, %
1.81%
Shrs. gr., 5y
-0.18%
Rev. gr., 5y
-11.53%
Revenues
1.85b
-14.91%
717,180,0471,006,318,9651,153,937,5491,307,399,6021,467,465,0051,903,335,2522,252,575,4862,784,900,0203,157,075,0753,302,519,1833,686,822,7753,807,661,7583,882,863,1783,361,025,7453,413,192,8853,346,704,6042,735,262,8372,820,561,0142,174,031,5781,849,908,044
Net income
-330m
L+3.89%
092,742,58298,131,064121,807,211195,558,577265,483,488333,268,224429,153,592478,439,227189,381,177384,862,604387,529,797-725,495,412141,895,201228,757,148243,772,732-426,389,850103,399,053-317,215,356-329,562,325
CFO
257m
+195.59%
95,772,39511,943,485189,259,328103,884,268115,660,561277,826,783288,014,258577,241,280541,581,197573,678,658380,616,139681,776,508214,297,431362,713,743366,657,366934,211,133345,299,144377,609,81286,873,036256,789,900
Dividend
Jun 07, 20240.066 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Guizhou Yibai Pharmaceutical Co., Ltd. is a Chinese pharmaceutical enterprise that encompasses the full spectrum of activities from researching and developing new drugs to their production and commercialization throughout the country. The company offers a diverse portfolio of medications, available in various dosage forms including capsules, tablets, granules, syrups, liquid injectables (small-volume), lyophilized powder injections, traditional pills, and oral solutions. These therapeutic agents are designed to address a broad range of medical conditions, specifically targeting oncology, cerebrovascular health, respiratory ailments, rheumatic diseases, digestive disorders, pediatric and gynecological illnesses, alongside providing anti-infective, anti-inflammatory, and pain management solutions. Established in 1995, the company maintains its headquarters in Guiyang, China.

Key people

Xianti Zeng
Finance Director · since 2024
Ya Dou
Deputy General Manager, Director · since 2011
Zhigang Feng
Deputy General Manager · since 2011
Jian Pu
Deputy General Manager · since 2024
Shenggui Zhang
Director of Marketing, Deputy General Manager · since 2011
Xiaohui Xia
Chief Engineer · since 2013
Xianhong Jiang
Deputy General Manager, Secretary of the Board · since 2024
Qi Dou
Chairman of the Board · since 2014
Yaqi Dou
Vice Chairman of the Board, General Manager · since 2024
Ning Gan
Director
Zhiwei Wang
Deputy General Manager, Director · since 2014
Yuexing Zhu
Director
Xuan Chen
Independent Director · since 2024
Geng Wang
Independent Director
Yonglin Wang
Independent Director · since 2007
Wu Zhang
Independent Director · since 2007
IPO date
Mar 23, 2004
Employees
Domiciled in
CN
Incorporated in
CN
Headquarters & legal address
贵州省贵阳市云岩区白云大道220-1号
贵阳市, GZ 100000
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT